ERBB2 and cancer: While this phenomenon had minimal impact on DC1-sensitized HER2-specific CD8+ T-cell-mediated cytotoxicity of cancer cells – likely attributable to minimal PD-1 expression on activated CD8+ T-cells after limited in vitro DC1 sensitization (64) – these data justify exploration of a multidimensional therapeutic approach using DC vaccination, targeted therapies, and PD-1/PD-L1 blockade in patients with oncogene-driven tumors.